GUFIC BIOSCIENCES LTD.
GUFICBIO · General/Diversified · NSE
₹297
Current Market Price
Fair Value (DCF)
₹63
Margin of Safety
-78.9%
Updated 8m ago
YieldIQ Score
35/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
41%
ROE
—
Debt/Equity
0.58
WACC
11.1%
Market Cap
₹2,973 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.0%
Return on capital employed
EV / EBITDA
27.1×
Enterprise multiple
Debt / EBITDA
2.8×
Leverage vs earnings
Interest Coverage
5.1×
EBIT covers interest
Current Ratio
1.61×
Short-term liquidity
Asset Turnover
0.64×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹296.5
Bear case
₹31.74
MoS -834.2%
Base case
₹62.61
MoS -373.6%
Bull case
₹88.4
MoS -235.4%
Ratio Trends
GUFICBIO · last 7 annual periods
ROE
11.6%
ROCE
14.7%
Operating Margin
—
Debt / Equity
0.56×
PE
103.2×
EV / EBITDA
14.5×
Historical Financials
GUFICBIO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹488 Cr | ₹779 Cr | ₹173 Cr | ₹195 Cr | ₹746 Cr | +11.2% |
| EBITDA | — | ₹150 Cr | ₹136 Cr | ₹147 Cr | ₹138 Cr | -2.0% |
| EBIT | ₹71.3 Cr | ₹132 Cr | ₹26.9 Cr | ₹30.8 Cr | — | -19.0% |
| PAT | ₹44.2 Cr | ₹95.8 Cr | ₹18.1 Cr | ₹20.0 Cr | ₹69.6 Cr | +12.0% |
| EPS (diluted) | ₹4.56 | ₹9.89 | ₹1.87 | ₹2.00 | — | -18.6% |
| CFO | ₹82.3 Cr | ₹104 Cr | ₹-26.6 Cr | ₹-7.5 Cr | ₹123 Cr | +10.5% |
| CapEx | — | — | — | — | ₹-75.5 Cr | — |
| FCF | — | — | — | — | ₹47.0 Cr | +0.0% |
| Total Assets | — | ₹521 Cr | ₹861 Cr | ₹1093 Cr | ₹1169 Cr | +22.4% |
| Total Debt | — | — | ₹121 Cr | ₹163 Cr | ₹336 Cr | +29.2% |
| Shareholders' Equity | — | — | ₹348 Cr | ₹533 Cr | ₹601 Cr | +14.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GUFICBIO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| ORCHPHARMA ORCHID PHARMA LIMITED | -28.8% | 29 | Overvalued | 7.9% | — |
| BLISSGVS BLISS GVS PHARMA LTD | -46.4% | 22 | Overvalued | 7.7% | — |
| RPGLIFE RPG LIFE SCIENCES LTD | -36.4% | 50 | Overvalued | 34.5% | — |
| IOLCP IOLCP | — | — | Pending | 6.0% | — |
| AARTIDRUGS AARTIDRUGS | — | — | Pending | 12.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for GUFICBIO in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. GUFIC BIOSCIENCES LTD. (GUFICBIO.NS) trades at 296.50 vs a model fair value of 62.61, a gap of -78.9%. Piotroski F-score: 5/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GUFICBIO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GUFICBIO →
Compare
Head-to-head with peers
Compare GUFICBIO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GUFICBIONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.